President Wants Curbs on Extensions of Drug Patents

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 12
Volume 11
Issue 12

WASHINGTON-President Bush has proposed policy changes to restrict the ability of drug companies to extend their patents past their expiration date. Mr. Bush said current federal laws and regulations try to balance the goals of innovation and accessibility.

WASHINGTON—President Bush has proposed policy changes to restrict the ability of drug companies to extend their patents past their expiration date. Mr. Bush said current federal laws and regulations try to balance the goals of innovation and accessibility.

New drugs have an average of 11 years patent protection before generic versions can be offered. However, companies can extend patent protection by seeking an automatic stay of expiration, which freezes the status quo until the legal questions are answered. Such stays are often based on items as seemingly trivial as the color of a bottle or a combination of ingredients unrelated to the product’s efficacy, the President said.

The FDA will issue a proposed rule that will permit only one automatic stay per generic drug application. Some patents, including those on packaging, will no longer be entitled to protections such as the 30-month automatic stay.

Recent Videos
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
Having all the necessary staff together, from medical oncologists to pharmacists, helps deliver the best possible outcomes to patients with cancer.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.